Jefferies Financial Group Inc. bought a new position in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 720,440 shares of the biopharmaceutical company's stock, valued at approximately $11,599,000. Jefferies Financial Group Inc. owned about 0.97% of Xencor as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of XNCR. Tower Research Capital LLC TRC lifted its holdings in Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company's stock valued at $44,000 after acquiring an additional 3,018 shares during the period. Allworth Financial LP acquired a new stake in shares of Xencor during the 2nd quarter worth approximately $55,000. E Fund Management Co. Ltd. purchased a new position in shares of Xencor during the 2nd quarter valued at approximately $79,000. iSAM Funds UK Ltd purchased a new position in shares of Xencor during the 2nd quarter valued at approximately $122,000. Finally, Prelude Capital Management LLC acquired a new position in shares of Xencor in the 3rd quarter valued at $139,000.
Xencor Price Performance
Shares of NASDAQ:XNCR opened at $28.88 on Friday. The business's 50 day moving average price is $19.54 and its 200-day moving average price is $14.69. Xencor, Inc. has a 1 year low of $7.83 and a 1 year high of $30.61. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of -13.31 and a beta of 0.85.
Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.51. The company had revenue of $51.22 million during the quarter, compared to analyst estimates of $18.89 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The firm's revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.41) EPS. On average, sell-side analysts expect that Xencor, Inc. will post -3 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on the stock. Wall Street Zen raised shares of Xencor from a "strong sell" rating to a "hold" rating in a report on Saturday, August 8th. Zacks Research upgraded shares of Xencor from a "strong sell" rating to a "hold" rating in a research report on Monday, July 6th. Truist Financial lowered their target price on shares of Xencor from $29.00 to $27.00 and set a "buy" rating on the stock in a research note on Tuesday, July 7th. JPMorgan Chase & Co. raised their target price on Xencor from $13.00 to $14.00 and gave the company a "neutral" rating in a research report on Monday, May 11th. Finally, Cantor Fitzgerald lifted their price target on Xencor from $43.00 to $44.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $24.86.
Get Our Latest Research Report on XNCR
Xencor Profile
(
Free Report)
Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.
The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.
Featured Stories
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
